DAVIS, Calif. (May 3, 2010) – Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, today announced that Vilmorin, one of the world’s oldest and largest producers and marketers of field crop and vegetable seeds, has purchased a 7.25% equity position in Arcadia.  In parallel, Arcadia has purchased a 35% ownership position in Limagrain Cereal Seeds LLC (LCS), a newly formed company that provides the platform for wheat development in the United States. Vilmorin maintains 65% ownership of LCS.

Vilmorin’s investment in Arcadia and the cooperation of the two companies in the management of LCS build upon a 2009 agreement related to the development of Nitrogen Use Efficient (NUE) wheat.  Under the new agreements, Vilmorin is granted worldwide privileged rights to technologies developed by Arcadia for wheat.

LCS, based in Fort Collins, Colo., will develop new wheat varieties based on genetic and breeding resources in Vilmorin and US-based programs, as well as advanced technologies from Vilmorin and Arcadia.  LCS has appointed Dr. C. James Peterson, Professor of Wheat Breeding and Genetics and former head of wheat breeding for Oregon State University, as VP of Research.

In order to diversify its genetic resources and to establish business in key production zones for American wheat, LCS has acquired the wheat assets of Genesis Seed Research and BSF AG Research (Indiana). Genetic material for high-quality wheat and an existing flow of royalties are the two main assets of these firms and constitute the building blocks for more ambitious development plans.

Wheat is the world’s second largest agricultural crop, with annual output valued at $73 billion.   As one of the major sources of global nutrition, supply and demand projections clearly underline the need for advancements in wheat productivity through traits that benefit growers, consumers, and the environment.  Arcadia and Vilmorin believe that their strategic alliance and partnership in LCS will reinforce Vilmorin’s current leadership position in global wheat genetics, and create a significant opportunity for LCS.

“The Vilmorin investment in Arcadia is a clear validation of our core technologies, our commitment to ongoing development of new technologies, and the strength of our management team,” said Eric Rey, president and CEO of Arcadia.  “In addition to being an equity investor, Vilmorin is the ideal joint venture partner because of our aligned vision about how to offer technologies to wheat growers that can improve crop quality, on-farm economics, and the overall impact of farming on the global environment.  Our participation in LCS is demonstrative of Arcadia’s strategy to capture more downstream value for its technologies in key crop areas.”

“Vilmorin’s wheat strategy in the US, one of the world’s main wheat markets, is based on the development of genetic material well adapted to local conditions, access to innovative new technologies and a team of experts dedicated to growing our wheat business. The long term collaboration with Arcadia is a key component of our global expansion plan and will allow us to develop more innovative and environmentally friendly seed varieties,” said Adrian Huige, CEO of Vilmorin.

About Arcadia Biosciences, Inc.

Based in Davis, Calif., with additional facilities in Seattle, Wash. and Phoenix, Ariz., Arcadia Biosciences is an agricultural technology company focused on developing technologies and products that improve the environment and enhance human health.  For more information visit www.arcadiabio.com.

About Vilmorin

Vilmorin is the fourth largest seed company in the world, and creates vegetable and field crops with high added value, thus helping to meet food needs more efficiently. Based on a responsible vision of its development, Vilmorin’s strategy is a successful combination of its research capacity and constant international growth that strengthens its position as a world player. This ambition is founded on sharing knowledge, quality of life and respect for the needs of mankind, all expressed through its philosophy “Cultivating the taste of life.”

Listed on NYSE Euronext Paris (compartment A), Vilmorin’s quotation is included in the Next 150, CAC Mid 100 and SBF 120 indices, and is eligible for SRD (Deferred Settlement Order). For more information visit www.vilmorin.info.

DAVIS, Calif. (March 12, 2010) – Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, announced today that it has successfully completed the first commercial production of SONOVA™ 400 High GLA Safflower Oil.  Seed produced by the first High GLA Safflower crop, grown during 2009, was processed to produce commercial quantities of SONOVA™ 400 oil, which is now available for distribution as a key ingredient in dietary supplements.  SONOVA™ 400 is being launched at SupplyExpo 2010 being held March 12-14 in Anaheim, Calif.

SONOVA™ 400, developed through a combination of plant breeding and modern biotechnology, delivers 400 milligrams (mg) of gamma-linolenic acid (GLA) per gram, making it the most concentrated, convenient and cost-effective source of GLA available.

GLA is an important nutritional omega-6 fatty acid with documented health benefits that are similar and complementary to the benefits of omega-3 fatty acids.  Numerous published studies show the benefits of GLA supplementation, including anti-inflammatory effects, and improved skin health and appearance.  A recent study by Schirmer and Phinney found that GLA supplementation also plays a key role in maintaining weight loss.

Currently, evening primrose and borage oils are the two main sources of dietary GLA, containing 10 percent and 20 percent GLA, respectively. The availability of SONOVA™ 400, with over 40 percent GLA – twice the GLA concentration of borage oil – provides consumers with the option of taking fewer capsules or smaller capsules to obtain their desired level of GLA supplementation.

In December, 2009, Arcadia announced that it had completed the U.S. Food and Drug Administration (FDA) regulatory process for SONOVA™ 400, allowing it to be marketed and sold as an ingredient in dietary supplements.

“Completion of our first oil processing run represents one more successful step along the pathway to commercializing this important new product,” said Eric Rey, president and CEO of Arcadia.  “Consumers and manufacturers have been asking for a more concentrated and cost-effective source of GLA.  Following successful completion of the FDA process, completion of this first production run and achieving our intended oil quality targets allows us to commercialize SONOVA™ 400, making the benefits of GLA more broadly available to consumers on a cost-effective basis.”

SONOVA™ 400 is marketed and sold by Bioriginal Food and Science Corporation, a global provider of essential fatty acid (EFA) solutions.

About Arcadia Biosciences, Inc.

Based in Davis, Calif., with additional facilities in Seattle, Wash. and Phoenix, Ariz., Arcadia Biosciences is an agricultural technology company focused on developing technologies and products that improve the environment and enhance human health.  For more information visit www.arcadiabio.com.

About Bioriginal Food and Science Corp.

Bioriginal Food and Science is a world leader in the production, marketing, and distribution of high-quality, innovative Essential Fatty Acid (EFA) solutions. The company’s EFA products are available in a full range of Omega-3, Omega-6 and Omega-9 oils from both marine and plant sources in various delivery formats. Headquartered in Saskatchewan, Canada, Bioriginal has state-of-the-art GMP production facilities in North America, Europe and Asia, and a global distribution network that spans six continents. For more information visit www.bioriginal.com.

To download a PDF version please, click here.

DAVIS, Calif. (February 15, 2010) — Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, today announced that it has received a two-year, $855,500 Small Business Technology Transfer (STTR) grant funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the American Recovery and Reinvestment Act (ARRA). The grant was awarded to Arcadia, in partnership with Washington State University (WSU), to help fund Phase II development of wheat varieties with reduced celiac disease-causing proteins.

Arcadia and WSU received a Phase I grant in 2005 through which the organizations applied TILLING®, a high-throughput genetic screening technology, to identify wheat plants with low levels of proteins that are most toxic to individuals with celiac disease. Significant progress in the Phase I program drove the Phase II application and grant funding. Phase II activities will take a broader approach and seek to remove a far greater number of toxic proteins while maintaining levels of proteins that are critical for bread-making qualities. The company also believes that removal of targeted toxic proteins could cause an increase in beneficial proteins and potentially lead to more nutritious bread.

Celiac disease is a digestive disorder that, in sensitive individuals, results from a toxic reaction to certain proteins found in specific grains, including wheat. This reaction in celiac sufferers causes damage to the small intestine and inhibits proper food absorption. It is estimated that approximately 1 percent of Americans have the disease, and the incidence is even higher in some northern European countries. A study by the University of Minnesota and the Mayo Clinic released in July 2009 found that celiac disease is four times more common today than it was 50 years ago. The study attributed this increase to the improvement in diagnostic tools as well as unknown environmental factors.

“Celiac disease sufferers have to make significant dietary adjustments in order to avoid potentially severe impacts. And while the range of food products continues to expand in response to the rising numbers of diagnosed celiac-sufferers, certain grains remain off-limits. Development of wheat varieties with minimal amounts of celiac-triggering proteins can dramatically expand food choices and the quality of life for celiac-sufferers,” said Eric Rey, president and CEO of Arcadia. “The progress under our Phase I grant has made us increasingly optimistic about our ability to deliver wheat varieties that people with celiac disease can enjoy. If the approach we are exploring in the Phase II grant is successful, our new wheat varieties may also appeal to a much broader market.”

The company has not released a commercialization timeline for its new wheat varieties, though it expects to complete Phase II research in mid-2011.

About Arcadia Biosciences, Inc.
Based in Davis, Calif., with additional facilities in Seattle, Wash. and Phoenix, Ariz., Arcadia Biosciences is an agricultural technology company focused on developing technologies and products that improve the environment and enhance human health. For more information visit www.arcadiabio.com.

* The project described was supported by Award Number R42DK072721 from the National Institute of Diabetes and Digestive and Kidney Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the National Institutes of Health.

To download a PDF version please, click here.